Cullinan Therapeutics (CGEM) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $14.00, +2.64% vs the prior close of $13.64.
- Volume 972.10K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CGEM rises 2.6% to $14.00. Closed at $14.00, +2.64% vs the prior close of $13.64. Day range $13.45–$14.18, opened at $13.62.
CGEM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CGEM rises 2.6% to $14.00
- Closed at $14.00, +2.64% vs the prior close of $13.64. Day range $13.45–$14.18, opened at $13.62.
- Volume was 972.10K shares, 1.0x its 50-day average of 976.98K.
- Price is -26.5% vs its 50-day average ($19.05) and -10.1% vs its 200-day average ($15.58).
- 52-week range $6.73–$23.19; today's close sits at 44% of that range, 39.6% below the 52-week high.
Oct 14, 2026 — CGEM slides 3.3% to $13.64, a 3-month low, 3 down days in a row
- Closed at $13.64, -3.26% vs the prior close of $14.10. Day range $13.44–$14.18, opened at $13.81.
- Volume was 903.50K shares, 0.9x its 50-day average of 972.20K.
- Price is -28.7% vs its 50-day average ($19.12) and -12.3% vs its 200-day average ($15.56).
- 52-week range $6.73–$23.19; today's close sits at 42% of that range, 41.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CGEM slides 5.7% to $14.10, a 3-month low
- Closed at $14.10, -5.69% vs the prior close of $14.95. Day range $14.07–$14.93, opened at $14.86.
- Volume was 590.30K shares, 0.6x its 50-day average of 968.13K.
- Price is -26.6% vs its 50-day average ($19.20) and -9.3% vs its 200-day average ($15.54).
- 52-week range $6.73–$23.19; today's close sits at 45% of that range, 39.2% below the 52-week high.
Oct 12, 2026 — CGEM slides 3.7% to $14.95
- Closed at $14.95, -3.73% vs the prior close of $15.53. Day range $14.88–$15.64, opened at $15.45.
- Volume was 372.40K shares, 0.4x its 50-day average of 977.47K — lighter than usual.
- Price is -22.3% vs its 50-day average ($19.24) and -3.7% vs its 200-day average ($15.52).
- 52-week range $6.73–$23.19; today's close sits at 50% of that range, 35.5% below the 52-week high.
Oct 9, 2026 — CGEM rises 0.5% to $15.53
- Closed at $15.53, +0.45% vs the prior close of $15.46. Day range $15.23–$15.95, opened at $15.41.
- Volume was 567.50K shares, 0.6x its 50-day average of 975.91K — lighter than usual.
- Price is -19.4% vs its 50-day average ($19.27) and +0.2% vs its 200-day average ($15.50).
- 52-week range $6.50–$23.19; today's close sits at 54% of that range, 33.0% below the 52-week high.
Oct 8, 2026 — CGEM dips 1.1% to $15.46
- Closed at $15.46, -1.09% vs the prior close of $15.63. Day range $14.81–$15.71, opened at $15.60.
- Volume was 1.14M shares, 1.2x its 50-day average of 964.05K.
- Price is -20.0% vs its 50-day average ($19.31) and -0.1% vs its 200-day average ($15.47).
- 52-week range $5.85–$23.19; today's close sits at 55% of that range, 33.3% below the 52-week high.
Oct 7, 2026 — CGEM slides 3.8% to $15.63
- Closed at $15.63, -3.82% vs the prior close of $16.25. Day range $15.47–$16.46, opened at $15.95.
- Volume was 808.20K shares, 0.8x its 50-day average of 959.33K.
- Price is -19.2% vs its 50-day average ($19.35) and +1.2% vs its 200-day average ($15.44).
- 52-week range $5.71–$23.19; today's close sits at 57% of that range, 32.6% below the 52-week high.
Oct 6, 2026 — CGEM rises 1.3% to $16.25 on 2.2x normal volume
- Closed at $16.25, +1.31% vs the prior close of $16.04. Day range $16.06–$17.70, opened at $17.24.
- Volume was 2.02M shares, 2.2x its 50-day average of 929.60K — unusually heavy trading.
- Price is -16.2% vs its 50-day average ($19.39) and +5.4% vs its 200-day average ($15.42).
- 52-week range $5.71–$23.19; today's close sits at 60% of that range, 29.9% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — CGEM jumps 3.4% to $16.04
- Closed at $16.04, +3.42% vs the prior close of $15.51. Day range $15.13–$16.55, opened at $15.59.
- Volume was 1.08M shares, 1.2x its 50-day average of 914.27K.
- Price is -17.4% vs its 50-day average ($19.41) and +4.3% vs its 200-day average ($15.38).
- 52-week range $5.68–$23.19; today's close sits at 59% of that range, 30.8% below the 52-week high.
Oct 2, 2026 — CGEM jumps 6.7% to $15.51
- Closed at $15.51, +6.74% vs the prior close of $14.53. Day range $14.59–$15.56, opened at $14.76.
- Volume was 1.16M shares, 1.3x its 50-day average of 898.40K.
- Price is -20.2% vs its 50-day average ($19.43) and +1.0% vs its 200-day average ($15.35).
- 52-week range $5.68–$23.19; today's close sits at 56% of that range, 33.1% below the 52-week high.
- SEC filings that day: 8-K.
CGEM latest news & SEC filings
Every SEC filing by or about CGEM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Michaelson Jennifer sold 8,000 shares at $21.57 (≈$172.56K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Michaelson Jennifer sold 30,000 shares at $20.26 (≈$607.80K) on Aug 13, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Michaelson Jennifer sold 8,000 shares at $17.82 (≈$142.56K) on Jul 6, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade CGEM
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 10, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.99% (largest 22.2%). That is a volatile stock.
- Liquidity: about 1.29M shares (≈$18.08M) trade per day on average.
- 52-week position: $14.00 vs a range of $6.73–$23.19 (44% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jennifer Michaelson sold 8,000 shares on Sep 8, 2026.
- Latest filings: 8-K Oct 2, 2026; 8-K Sep 24, 2026; 8-K Sep 14, 2026.
- Share count: 64.35M shares outstanding (Jul 31, 2026), +8.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CGEM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 13.62 | 14.18 | 13.45 | 14.00 | 972.10K |
| Oct 14, 2026 | 13.81 | 14.18 | 13.44 | 13.64 | 903.50K |
| Oct 13, 2026 | 14.86 | 14.93 | 14.07 | 14.10 | 590.30K |
| Oct 12, 2026 | 15.45 | 15.64 | 14.88 | 14.95 | 372.40K |
| Oct 9, 2026 | 15.41 | 15.95 | 15.23 | 15.53 | 567.50K |
| Oct 8, 2026 | 15.60 | 15.71 | 14.81 | 15.46 | 1.14M |
| Oct 7, 2026 | 15.95 | 16.46 | 15.47 | 15.63 | 808.20K |
| Oct 6, 2026 | 17.24 | 17.70 | 16.06 | 16.25 | 2.02M |
| Oct 5, 2026 | 15.59 | 16.55 | 15.13 | 16.04 | 1.08M |
| Oct 2, 2026 | 14.76 | 15.56 | 14.59 | 15.51 | 1.16M |
| Oct 1, 2026 | 15.22 | 15.39 | 14.49 | 14.53 | 910.80K |
| Sep 30, 2026 | 15.39 | 15.78 | 14.95 | 15.35 | 1.07M |
| Sep 29, 2026 | 15.00 | 15.44 | 14.68 | 15.23 | 1.24M |
| Sep 28, 2026 | 14.71 | 15.19 | 14.20 | 14.95 | 1.11M |
| Sep 25, 2026 | 15.62 | 15.62 | 14.67 | 14.81 | 1.72M |
| Sep 24, 2026 | 16.60 | 16.88 | 14.80 | 15.44 | 2.73M |
| Sep 23, 2026 | 21.67 | 21.67 | 16.78 | 16.87 | 2.59M |
| Sep 22, 2026 | 21.44 | 21.88 | 21.26 | 21.67 | 831.80K |
| Sep 21, 2026 | 21.45 | 21.78 | 20.98 | 21.35 | 763.90K |
| Sep 18, 2026 | 21.38 | 21.45 | 20.63 | 21.08 | 3.25M |
About Cullinan Therapeutics
Cullinan Therapeutics (CGEM) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1789972.
CGEM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Nadim Ahmed | President and CEO | Feb 25, 2026 |
| Andrew R Allen | Director | Jun 18, 2026 |
| Mittie Doyle | Director | Jun 18, 2026 |
| David D. Meek | Director | Jun 18, 2026 |
| Anthony Rosenberg | Director | Jun 18, 2026 |
| Mary Thistle | Director | Jun 18, 2026 |
| Stephen W Webster | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Nadim Ahmed | President and CEO | Feb 25, 2026 |
| Mary Kay Fenton | Chief Financial Officer | Jul 2, 2026 |
| Jeffrey Alan Jones | Chief Medical Officer | Feb 25, 2026 |
| Jennifer Michaelson | Chief Scientific Officer | Sep 10, 2026 |
| Jacquelyn L Sumer | Chief Legal Officer | Jul 2, 2026 |
| Corrine Savill | Chief Business Officer | Feb 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Jennifer Michaelson | Sale | 8,000 | $21.57 |
| Aug 13, 2026 | Jennifer Michaelson | Sale | 30,000 | $20.26 |
| Jul 6, 2026 | Jennifer Michaelson | Sale | 8,000 | $17.82 |
| May 5, 2026 | Jennifer Michaelson | Sale | 200 | $15.58 |
| May 5, 2026 | Jennifer Michaelson | Sale | 7,800 | $14.60 |
| Mar 5, 2026 | Jennifer Michaelson | Sale | 8,000 | $15.68 |
| Feb 25, 2026 | Jennifer Michaelson | Sale | 1,780 | $14.14 |
| Feb 24, 2026 | Jeffrey Alan Jones | Sale | 4,582 | $14.47 |
| Feb 24, 2026 | Jacquelyn L Sumer | Sale | 3,601 | $14.47 |
| Feb 24, 2026 | Nadim Ahmed | Sale | 13,515 | $14.47 |
| Feb 24, 2026 | Jennifer Michaelson | Sale | 3,601 | $14.47 |
| Feb 23, 2026 | Jennifer Michaelson | Sale | 1,752 | $13.99 |
| Feb 20, 2026 | Jeffrey Alan Jones | Sale | 4,982 | $13.62 |
| Feb 20, 2026 | Mary Kay Fenton | Sale | 4,398 | $13.62 |
| Feb 20, 2026 | Jacquelyn L Sumer | Sale | 3,742 | $13.62 |
CGEM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-219.88M | — | $-175.75M |
| Dec 31, 2024 | — | $-167.38M | — | $-145.30M |
| Dec 31, 2023 | — | $-153.16M | -3.69 | $-134.28M |
| Dec 31, 2022 | $0 | $111.21M | 2.38 | $-126.66M |
| Dec 31, 2021 | $18.94M | $-65.57M | -1.52 | $-43.43M |
Latest balance sheet: total assets $363.79M, total liabilities $42.03M, cash $78.64M (as of Jun 30, 2026).
CGEM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $17.95 |
| May 7, 2026 | 8-K Item 2.02 (results) | $14.72 |
| Mar 10, 2026 | 8-K Item 2.02 (results) | $14.91 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $11.14 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $7.35 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $7.03 |
| May 8, 2025 | 8-K Item 2.02 (results) | $7.77 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $8.61 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $15.58 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CGEM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.